The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and disappointing return on equity. Get the full Vertex Pharmaceuticals Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE. 2. As of noon trading, Regeneron Pharmaceuticals ( REGN ) is down $2.98 (-1.1%) to $263.99 on light volume Thus far, 302,893 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $263.67-$269.78 after having opened the day at $265.79 as compared to the previous trading day's close of $266.97. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally.